Document is current
Any future updates will be listed below
-
Authors
Dispenzieri, Angela https://orcid.org/0000-0001-8780-9512
Kastritis, Efstathios https://orcid.org/0000-0001-8191-5832
Wechalekar, Ashutosh D. https://orcid.org/0000-0002-4406-7237
Schönland, Stefan O. https://orcid.org/0000-0002-4853-5579
Kim, Kihyun
Sanchorawala, Vaishali https://orcid.org/0000-0002-6307-2445
Landau, Heather J. https://orcid.org/0000-0002-3152-1189
Kwok, Fiona
Suzuki, Kenshi https://orcid.org/0000-0001-7132-5337
Comenzo, Raymond L.
Berg, Deborah
Liu, Guohui
Kumar, Arun
Faller, Douglas V. https://orcid.org/0000-0002-2454-3478
Merlini, Giampaolo https://orcid.org/0000-0001-7680-3254
-
Funding
Funding for this research was provided by:
Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
- License Information
-
More Information
Article History
Received: 12 January 2021
Revised: 26 May 2021
Accepted: 2 June 2021
First Online: 24 June 2021
Competing interests
: AD, reports grants from Takeda, Celgene, Alnylam, and Pfizer for trial support, and research support from Janssen, outside the submitted work. EK, reports personal fees from Takeda, during the conduct of the study; grants and personal fees from Amgen, personal fees and non-financial support from Genesis Pharma, grants, personal fees and non-financial support from Janssen, personal fees from Prothena, personal fees from Pfizer, outside the submitted work. ADW, reports research funding from Amgen and Honoraria from Janssen-Cilag, Takeda, GSK, and Celgene. SOS, reports grants, personal fees and non-financial support from Janssen, grants, personal fees and non-financial support from Prothena, grants and non-financial support from Sanofi, non-financial support from MSD, personal fees and non-financial support from Takeda, outside the submitted work. KK, reports grants and personal fees from Celgene, for honoraria, consulting or advisory roles and personal fees from Takeda, Amgen, and Janssen, for honoraria, consulting or advisory role outside the submitted work. VS, reports grants from Takeda, Celgene, Prothena, Janssen, and consulting or advisory role from AbbVie, Proclara, Caleum, during the conduct of the study. HJL, reports grants from Genzyme Corporation, Amgen, Takeda Pharmaceuticals, Janssen Scientific Affairs LLC, HCA Healthcare, Spectrum Pharmaceuticals, Inc, Caelum Biosciences, Inc, Celgene, Clinical Care Options, Karyopharm, outside the submitted work. FK, has nothing to disclose. KS, reports research funding from BMS and honoraria from Takeda, BMS, Janssen and Celgene. RLC, received steering committee personal fees from Takeda, during the conduct of the study; grants to institution and personal steering committee fees from Janssen, personal DSCM fees from Sanofi, grants for laboratory research and personal DSCM fees from UNUM, grants to institution for clinical trial and personal steering committee fees from Takeda, grants to institution for clinical trial and personal fees for an advisory board from Karyopharm, personal fees for an advisory board from Amgen, grants to institution for clinical trial and personal steering committee fees from Prothena, personal fees for an advisory board from Caelum Biosciences, outside the submitted work. DB, is an employee of Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. GL, is an employee of Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. AK, is an employee of Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. DVF, is an employee of Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. GM has nothing to disclose.
